Switching between anti-CGRP monoclonal antibodies and gepants

Session 4: Current strategies and the future ahead

Taoufik Alsaadi

MD, Chairman, Neurology Department, Chief Medical Officer, American Center for Psychiatry & Neurology (ACPN), Abu Dhabi

Download presentation

Can we modify the course of migraine?

You Might Also Like

Related Embedded Video Item Thumbnail Should we use combination therapy in migraine treatment? Con
Related Embedded Video Item Thumbnail Should we use combination therapy in migraine treatment? Pro
Related Embedded Video Item Thumbnail Children and adolescent as migraine patients - Diagnosis and management
Related Embedded Video Item Thumbnail Should we treat during the prodromal phase? Pro
Related Embedded Video Item Thumbnail Should we treat during the prodromal phase? Con